CONNECT BIOPHARMA HOLDINGS LIMITED Connect Biopharma Holdings Limited Share Price
Equities
CNTB
US2075231017
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 USD | -1.47% |
|
-12.99% | +13.56% |
| 17/04 | Sector Update: Health Care Stocks Retreating Late Afternoon | MT |
| 17/04 | Sector Update: Health Care | MT |
| Sales 2024 * | 1.14B 158M 13.14B | Sales 2025 * | 256M 35.31M 2.94B | Capitalization | 535M 73.84M 6.16B |
|---|---|---|---|---|---|
| Net income 2024 * | -215M -29.67M -2.47B | Net income 2025 * | -438M -60.45M -5.04B | EV / Sales 2024 * | -0.26 x |
| Net cash position 2024 * | 830M 115M 9.55B | Net cash position 2025 * | 1.49B 205M 17.11B | EV / Sales 2025 * | -3.72 x |
| P/E ratio 2024 * |
-2.49
x | P/E ratio 2025 * |
-1.77
x | Employees | 81 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 56.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Connect Biopharma Holdings Limited
More recommendations
More press releases
| 1 day | -1.47% | ||
| 1 week | -12.99% | ||
| Current month | -22.99% | ||
| 1 month | +0.75% | ||
| 3 months | +5.51% | ||
| 6 months | +17.07% | ||
| Current year | +13.56% |
1 week
1.28
1.54
1 month
1.282.66
Current year
0.902.66
1 year
0.532.84
3 years
0.5329.27
5 years
0.5329.27
10 years
0.5329.27
| Managers | Title | Age | Since |
|---|---|---|---|
Zheng Wei
FOU | Founder | 61 | 23/15/23 |
Wubin Pan
FOU | Founder | 60 | 01/12/01 |
Steven Chan
DFI | Director of Finance/CFO | 52 | 22/21/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jean Liu
BRD | Director/Board Member | 55 | 23/21/23 |
| Director/Board Member | 66 | 01/20/01 | |
Karen Wilson
BRD | Director/Board Member | 61 | 01/20/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.34 | -1.47% | 58,379 |
| 25/24/25 | 1.36 | -0.73% | 33,937 |
| 24/24/24 | 1.37 | -1.44% | 41,055 |
| 23/24/23 | 1.39 | +2.96% | 73,419 |
| 22/24/22 | 1.35 | -12.34% | 51,033 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of T cell-driven inflammatory diseases. The Companyâs lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Ra) in development for the treatment of atopic dermatitis and asthma. Its second advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Companyâs third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis (AD). It has clinical development activities in the United States, the Peopleâs Republic of China (PRC), Europe, and Australia and operations in those geographies, as well as Hong Kong. Its subsidiaries include Connect Biopharma HongKong Limited, Connect Biopharm LLC and others.
Calendar
10/09/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.34
USD
Average target price
7
USD
Spread / Average Target
+422.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.56% | 73.84M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CNTB Stock
